var data={"title":"Terbutaline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Terbutaline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7022?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=terbutaline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Terbutaline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=terbutaline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Terbutaline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14640925\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Prolonged tocolysis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Terbutaline has not been approved and should not be used for prolonged tocolysis (beyond 48 to 72 hours). In particular, terbutaline should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline to pregnant women. In mothers, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225677\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bricanyl Turbuhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225725\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote, Extravasation;</li>\n      <li>\n        Beta<sub>2</sub> Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225681\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma/bronchospasm:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 5 mg 3 times daily (approximately every 6 hours); reduce dose to 2.5 mg 3 times daily if side effects occur; maximum: 15 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 0.25 mg/dose; may repeat in 15 to 30 minutes (maximum: 0.5 mg/4-hour period)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Off-label dose: 0.25 mg/dose; may repeat every 20 minutes for 3 doses (maximum: 0.75 mg/1-hour period) (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation: Bricanyl Turbuhaler [Canadian product]: One inhalation (0.5 mg) as needed; if not effective after 5 minutes may repeat dose. If second dose is not effective, consult healthcare provider immediately. Additional doses may be administered however &gt;6 inhalations in a 24 hour period should not be needed. <b>Note:</b> If adequate relief is not obtained with previously effective dose, or if effects of inhalation last &lt;3 hours, patient should be reassessed promptly; may indicate worsening asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation management, sympathomimetic vasoconstrictors (off-label use; based on limited case reports):</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Large extravasations: Infiltrate extravasation area using a solution of 1 mg diluted in 10 mL of 0.9% sodium chloride; volume of terbutaline solution administered varied from 3 to 10 mL (Stier 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Small/distal extravasations: Infiltrate extravasation area using a solution of 1 mg diluted in 1 mL of 0.9% sodium chloride; volume of terbutaline solution administered varied from 0.5 to 1 mL (Stier 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Premature labor (acute; short-term [&le;72 hours] tocolysis) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 2.5 to 5 mcg/minute; increased gradually every 20 to 30 minutes by 2.5 to 5 mcg/minute up to a maximum of 25 mcg/minute; decrease to the lowest effective dose once contractions are controlled (Mackeen 2014; Travis 1993).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 0.25 mg every 20 minutes to 3 hours; hold for pulse &gt;120 beats per minute. Terbutaline has not been approved for and should not be used for prolonged tocolysis (beyond 48 to 72 hours) (ACOG 171 2016; Hearne 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225702\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=terbutaline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Terbutaline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma/bronchospasm:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years to Adolescents &le;15 years: 2.5 mg 3 times daily (approximately every 6 hours); maximum: 7.5 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &gt;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;12 years (off-label dose): 0.01 mg/kg every 20 minutes for 3 doses, then every 2 to 6 hours as needed (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;12 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation: Bricanyl Turbuhaler [Canadian product]: Children &ge;6 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225682\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225683\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15245730\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225654\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225639\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950984\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bricanyl Turbuhaler: 500 mcg/actuation [100 or 200 metered actuations]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225657\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Use infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: Bricanyl Turbuhaler [Canadian product]: After removing lid, patient should hold inhaler upright and turn blue grip as far as it will go in one direction then turn it back to original position. Clicking sound indicates that inhaler is ready for use. Patient should exhale fully but not into the inhaler and then place mouthpiece gently between teeth, close lips around inhaler and inhale deeply. Inhaler should be removed from mouth prior to exhaling. Instruct patients to rinse mouth with water after each inhalation as some medication may stick to the inside of the mouth and throat. If inhaler is dropped or shaken, or if patient exhales into the inhaler after a dose is loaded, the dose will be lost and a new dose should be loaded and inhaled. Outside of mouthpiece should be cleaned once weekly with a dry tissue. Instruct patient to keep inhaler dry. First appearance of red mark in dose indicator (window underneath mouthpiece) indicates that 20 doses remain. When red mark reaches bottom of dose indicator no doses remain and Turbuhaler should be discarded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">inSubQ: Extravasation management, sympathomimetic vasopressors (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Infiltrate extravasation area with terbutaline solution 1 mg diluted with 10 mL (large extravasation site) <b>or</b> 1 mg diluted in 1 mL (small/distal extravasation site) of 0.9% sodium chloride into extravasation site (Stier 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225655\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Asthma/Bronchospasm:</b> Prevention and reversal of bronchospasm in patients &ge;12 years of age with asthma and reversible bronchospasm associated with bronchitis and emphysema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470443\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Extravasation management, sympathomimetic vasoconstrictors; Premature labor (acute; short-term [&le;72 hours] tocolysis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225734\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Brethine may be confused with Methergine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbutaline may be confused with terbinafine, TOLBUTamide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbutaline and methylergonovine parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225646\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Nervousness, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum potassium, increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, drowsiness, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiac arrhythmia, chest pain, hyperglycemia (preterm labor), hypokalemia (preterm labor), hypotension (preterm labor), ischemic heart disease (preterm labor), myocardial infarction (preterm labor), paradoxical bronchospasm, pulmonary edema (preterm labor)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225661\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to terbutaline, sympathomimetic amines, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Additional contraindications: Prolonged (&gt;48 to 72 hours) tocolysis, especially for maintenance in the outpatient setting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Additional contraindications: Acute or maintenance tocolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bricanyl Turbuhaler [Canadian product]: History of tachyarrhythmias; as tocolytic in patients at risk of premature labor or threatened abortion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225643\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Appropriate use: When used as a bronchodilator, optimize anti-inflammatory treatment before initiating maintenance treatment with terbutaline. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest form of asthma (Step 1 and/or exercise-induced) would not require concurrent use based upon asthma guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta<sub>2</sub>-agonists may also increase risk of arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia or taking concomitant drugs that cause hypokalemia; beta<sub>2</sub>-agonists may decrease serum potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Preterm labor:<b> [US Boxed Warning]: Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48 to 72 hours). Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate.</b> Oral terbutaline is contraindicated for acute or chronic use in the management of preterm labor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300114\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225648\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9977&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225650\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14206279\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Terbutaline crosses the placenta; umbilical cord concentrations are ~11% to 48% of maternal blood levels.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, pre-eclampsia, preterm birth, low birth weight infants). Terbutaline is not recommended for the treatment of asthma during pregnancy; inhaled beta<sub>2</sub>-receptor agonists are preferred (NAEPP 2005).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48 to 72 hours).</b> Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate. Terbutaline has been used in the management of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 171 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13763352\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Terbutaline is excreted in breast milk; concentrations are similar to or higher than those in the maternal plasma. Based on information from four cases, exposure to the breast-fed infant would be &lt;1% of the weight-adjusted maternal dose. Adverse events were not observed in nursing infants (Bor&eacute;us 1982; L&ouml;nnerholm 1982). The manufacturer recommends that terbutaline be used in breast-feeding women only if the potential benefit to the mother outweighs the possible risk to the infant. The use of beta<sub>2</sub>-receptor agonists are not considered a contraindication to breast-feeding (NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225652\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum potassium, glucose; intake/output; heart rate, blood pressure, respiratory rate; chest pain, shortness of breath; monitor for signs and symptoms of pulmonary edema (when used as a tocolytic); monitor FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests (when used as bronchodilator). If used for extravasation management, monitor and document extravasation site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225642\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Relaxes bronchial and uterine smooth muscle by action on beta<sub>2</sub>-receptors with less effect on heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225660\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 30 to 45 minutes; SubQ: 6 to 15 minute; Inhalation: 5 minutes (maximum effect: 15 to 60 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: 4 to 8 hours; Oral inhalation: 3 to 6 hours; SubQ: 1.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: 33% to 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 25%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive sulfate conjugates </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ doses are more bioavailable than oral </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 5.7 hours (range: 2.9 to 14 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% as unchanged drug); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225663\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Terbutaline Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Terbutaline Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $544.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $664.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038836\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asmalin (SG);</li>\n      <li>Asmaline (TH);</li>\n      <li>Asthmasian (TH);</li>\n      <li>Ataline (LK, MY);</li>\n      <li>Beta-2 (KR);</li>\n      <li>Betamic (BD);</li>\n      <li>Brethin (LK);</li>\n      <li>Bricalin (IL);</li>\n      <li>Bricanil (VE);</li>\n      <li>Bricanyl (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, CZ, DK, EG, ET, FI, FR, GB, GH, GM, GN, GY, HK, HN, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Bricanyl Depot (NO);</li>\n      <li>Bricanyl retard (NL);</li>\n      <li>Bricanyl Turbuhaler (HU, PL);</li>\n      <li>Bricasma (ID);</li>\n      <li>Bricasol (BD);</li>\n      <li>Britaline (MY);</li>\n      <li>Bronchodam (PH);</li>\n      <li>Bronco Asmo (TH);</li>\n      <li>Bronconyl (TH);</li>\n      <li>Brothine (TW);</li>\n      <li>Bucanil (MY);</li>\n      <li>Bucaril (TH);</li>\n      <li>Butaline (MY);</li>\n      <li>Contimit (DE);</li>\n      <li>Draconyl (GR);</li>\n      <li>Getran (TW);</li>\n      <li>Glin (TW);</li>\n      <li>Nairet (VN);</li>\n      <li>Nairex (ID);</li>\n      <li>Neoterb (AE, KW, QA);</li>\n      <li>Pulmoxel (PH);</li>\n      <li>Samisil (BD);</li>\n      <li>Talin (QA);</li>\n      <li>Tebif (LK);</li>\n      <li>Terbasmin (ES, IT);</li>\n      <li>Terbron (MY);</li>\n      <li>Terbu Expectorant (TH);</li>\n      <li>Terbul (LU);</li>\n      <li>Terbulin (BD, IL);</li>\n      <li>Terburop (CO, EC);</li>\n      <li>Terbutalin AL (HU);</li>\n      <li>Terbutalin Stada (PL);</li>\n      <li>Terbutil (BR);</li>\n      <li>Tervent (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27661654\"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi: 10.1097/AOG.0000000000001711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/27661654/pubmed\" target=\"_blank\" id=\"27661654\">27661654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkman ND, Thorp JM Jr, Hartmann KE, et al, &quot;Management of Preterm Labor,&quot; Evidence Report/Technology Assessment No. 18 (Prepared by Research Triangle Institute under Contract No. 290-97-0011). AHRQ Publication No. 01-E021. Rockville (MD) Agency for Healthcare Research and Quality. December 2000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/11127122/pubmed\" target=\"_blank\" id=\"11127122\">11127122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bohn D, Kalloghlian A, Jenkins J, et al, &ldquo;Intravenous Salbutamol in the Treatment of Status Asthmaticus in Children,&rdquo; <i>Crit Care Med</i>, 1984, 12(10):892-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/6435957/pubmed\" target=\"_blank\" id=\"6435957\">6435957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bor&eacute;us LO and de Ch&acirc;teau PU, &quot;Terbutaline in Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1982, 13(5):731-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7082542/pubmed\" target=\"_blank\" id=\"7082542\">7082542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bricanyl Turbuhaler (terbutaline) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canny GJ and Levison H, &ldquo;Aerosols - Therapeutic Use and Delivery in Childhood Asthma,&rdquo; <i>Ann Allergy</i>, 1988, 60(1):11-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/3276242/pubmed\" target=\"_blank\" id=\"3276242\">3276242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuglsang G, Pedersen S, and Borgstrom L, &ldquo;Dose-Response Relationships of I.V. Administered Terbutaline in Children With Asthma,&rdquo; <i>J Pediatr</i>, 1989, 114(2):315-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2915294/pubmed\" target=\"_blank\" id=\"2915294\">2915294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldenhersh N and Rachelefsky GS, &ldquo;Childhood Asthma: Management,&rdquo; <i>Pediatr Rev</i>, 1989, 10(9):259-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2652119/pubmed\" target=\"_blank\" id=\"2652119\">2652119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guinn DA, Goepfert AR, Owen J, et al, &ldquo;Terbutaline Pump Maintenance Therapy for Prevention of Preterm Delivery: A Double-Blind Trial,&rdquo; <i>Am J Obstet Gynecol</i>, 1998, 179(4):874-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/9790362/pubmed\" target=\"_blank\" id=\"9790362\">9790362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hearne AE and Nagey DA, &quot;Therapeutic Agents in Preterm Labor: Tocolytic Agents,&quot; <i>Clin Obstet Gynecol</i> 2000, 43(4):787-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/11100296/pubmed\" target=\"_blank\" id=\"11100296\">11100296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly HW, McWilliams BC, Katz R, et al, &ldquo;Safety of Frequent High Dose Nebulized Terbutaline in Children With Acute Severe Asthma,&rdquo; <i>Ann Allergy</i>, 1990, 64(2 Pt 2):229-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2301784/pubmed\" target=\"_blank\" id=\"2301784\">2301784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam F, Gill P, Smith M, et al, &ldquo;Use of the Subcutaneous Terbutaline Pump for Long-Term Tocolysis,&rdquo; <i>Obstet Gynecol</i>, 1998, 72(5):810-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&ouml;nnerholm G and Lindstr&ouml;m B, &quot;Terbutaline Excretion Into Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1982, 13(5):729-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7082541/pubmed\" target=\"_blank\" id=\"7082541\">7082541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, &quot;Guidelines for the Diagnosis and Management of Asthma,&quot; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo; <i>J Allergy Clin Immunol</i>, 1985, 76(3):409-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2863296/pubmed\" target=\"_blank\" id=\"2863296\">2863296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simhav HN and Caritis SN, &ldquo;Prevention of Preterm Delivery,&rdquo; <i>N Engl J Med</i>, 2007, 357(5):477-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/17671256/pubmed\" target=\"_blank\" id=\"17671256\">17671256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9928712\"></a>Stier PA, Bogner MP, Webster K, et al, &quot;Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia,&quot; <i>Am J Emerg Med</i>, 1999, 17(1):91-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/9928712/pubmed\" target=\"_blank\" id=\"9928712\">9928712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terbutaline sulfate injection [package insert]. Bedford, OH: Bedford Laboratories; April 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terbutaline sulfate tablet [package insert]. Hayward, CA: Impax Generics; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tipton WR and Nelson HS, &ldquo;Frequent Parenteral Terbutaline in the Treatment of Status Asthmaticus in Children,&rdquo; <i>Ann Allergy</i>, 1987, 58(4):252-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/3565860/pubmed\" target=\"_blank\" id=\"3565860\">3565860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Travis BE and McCullough JM, &ldquo;Pharmacotherapy of Preterm Labor,&rdquo; <i>Pharmacotherapy</i>, 1993, 13(1):28-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/8437965/pubmed\" target=\"_blank\" id=\"8437965\">8437965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zehner WJ Jr, Scott JM, Iannolo PM, et al, &ldquo;Terbutaline vs Albuterol for Out-of-Hospital Respiratory Distress: Randomized Double-Blind Trial,&rdquo; <i>Acad Emerg Med</i>, 1995, 2(8):686-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7584746/pubmed\" target=\"_blank\" id=\"7584746\">7584746</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9977 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F14640925\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F225677\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F225725\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F225681\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F225702\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F225682\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F225683\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15245730\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F225654\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F225639\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950984\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F225657\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F225655\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470443\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F225734\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F225646\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F225661\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F225643\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300114\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F225648\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F225650\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14206279\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13763352\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F225652\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F225642\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F225660\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F225663\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038836\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9977|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=terbutaline-patient-drug-information\" class=\"drug drug_patient\">Terbutaline: Patient drug information</a></li><li><a href=\"topic.htm?path=terbutaline-pediatric-drug-information\" class=\"drug drug_pediatric\">Terbutaline: Pediatric drug information</a></li></ul></div></div>","javascript":null}